Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Par Planning Megace ES Launch In Summer 2005 With In-House Sales Force

This article was originally published in The Pink Sheet Daily

Executive Summary

Par is looking for a second product to detail with the 50-60 person force it is building for extra strength Megace. The company hopes to get an "approvable" letter for the product in April and begin detailing in July.

You may also be interested in...



Par Expects Megace ES Label To Reflect Dosing, Bioavailability Advantages

The company is in discussions with FDA on labeling for the new formulation of megestrol oral suspension. The product’s user fee date was extended by three months to July 29 following FDA’s request, and Par’s submission, of supplemental data supporting the 505(b)(2) NDA.

Par Expects Megace ES Label To Reflect Dosing, Bioavailability Advantages

The company is in discussions with FDA on labeling for the new formulation of megestrol oral suspension. The product’s user fee date was extended by three months to July 29 following FDA’s request, and Par’s submission, of supplemental data supporting the 505(b)(2) NDA.

Par’s Megace Extra Strength May Launch With Contract Sales Force

The company will likely seek an exclusive sales force of 40 to 80 reps for the reformulated version of Bristol’s megestrol oral suspension product. Par expects to launch in mid-2005; its 505(b)(2) NDA has a user fee date of April 29.

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel